PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-47.91%
Both yoy net incomes decline, with AVGO at -21.38%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
5.00%
D&A growth well above AVGO's 2.50%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
-24.59%
Both lines show negative yoy. Martin Whitman would see an industry or cyclical factor reducing tax deferrals for both players.
0.38%
Less SBC growth vs. AVGO's 21.43%, indicating lower equity issuance. David Dodd would confirm the firm still retains key staff.
-181.26%
Negative yoy working capital usage while AVGO is 100.00%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
-314.91%
AR is negative yoy while AVGO is 781.82%. Joel Greenblatt would see a short-term cash advantage if revenue remains unaffected vs. competitor's approach.
89.50%
Some inventory rise while AVGO is negative at -163.64%. John Neff would see competitor possibly benefiting from leaner stock if demand remains.
26.52%
A yoy AP increase while AVGO is negative at -383.33%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
-174.24%
Both reduce yoy usage, with AVGO at -9.52%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
-160.65%
Negative yoy while AVGO is 99.50%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-102.24%
Both yoy CFO lines are negative, with AVGO at -13.95%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
35.99%
CapEx growth well above AVGO's 8.22%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
-100.00%
Negative yoy acquisition while AVGO stands at 0.00%. Joel Greenblatt sees potential short-term cash advantage unless competitor’s deals yield big synergy.
-27.11%
Negative yoy purchasing while AVGO stands at 0.00%. Joel Greenblatt sees a near-term liquidity advantage unless competitor’s new investments produce outsized returns.
42.29%
Liquidation growth of 42.29% while AVGO is zero at 0.00%. Bruce Berkowitz sees a mild difference in monetizing portfolio items that must be justified by market valuations.
-28.00%
Both yoy lines negative, with AVGO at -800.00%. Martin Whitman suspects a cyclical or strategic rationale for cutting extra invests in the niche.
-2.00%
Both yoy lines negative, with AVGO at -2.70%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
95.20%
Debt repayment growth of 95.20% while AVGO is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
92.91%
We slightly raise equity while AVGO is negative at -37.50%. John Neff sees competitor possibly preserving share count or buying back shares.
No Data
No Data available this quarter, please select a different quarter.